119 related articles for article (PubMed ID: 26004579)
1. Recent advances for FLAP inhibitors.
Pettersen D; Davidsson Ö; Whatling C
Bioorg Med Chem Lett; 2015 Jul; 25(13):2607-12. PubMed ID: 26004579
[TBL] [Abstract][Full Text] [Related]
2. Drug discovery approaches targeting 5-lipoxygenase-activating protein (FLAP) for inhibition of cellular leukotriene biosynthesis.
Gür ZT; Çalışkan B; Banoglu E
Eur J Med Chem; 2018 Jun; 153():34-48. PubMed ID: 28784429
[TBL] [Abstract][Full Text] [Related]
3. 4,5-Diarylisoxazol-3-carboxylic acids: A new class of leukotriene biosynthesis inhibitors potentially targeting 5-lipoxygenase-activating protein (FLAP).
Banoglu E; Çelikoğlu E; Völker S; Olgaç A; Gerstmeier J; Garscha U; Çalışkan B; Schubert US; Carotti A; Macchiarulo A; Werz O
Eur J Med Chem; 2016 May; 113():1-10. PubMed ID: 26922224
[TBL] [Abstract][Full Text] [Related]
4. Structure-based drug design on membrane protein targets: human integral membrane protein 5-lipoxygenase-activating protein.
Ferguson AD
Methods Mol Biol; 2012; 841():267-90. PubMed ID: 22222457
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of C(5)-substituted derivatives of leukotriene biosynthesis inhibitor BRP-7.
Levent S; Gerstmeier J; Olgaç A; Nikels F; Garscha U; Carotti A; Macchiarulo A; Werz O; Banoglu E; Çalışkan B
Eur J Med Chem; 2016 Oct; 122():510-519. PubMed ID: 27423639
[TBL] [Abstract][Full Text] [Related]
6. Targeting 5-lipoxygenase-activating protein in asthma and chronic obstructive pulmonary disease.
Antoniu SA
Expert Opin Ther Targets; 2014 Nov; 18(11):1285-92. PubMed ID: 25213852
[TBL] [Abstract][Full Text] [Related]
7. Novel leukotriene biosynthesis inhibitors (2012-2016) as anti-inflammatory agents.
Werz O; Gerstmeier J; Garscha U
Expert Opin Ther Pat; 2017 May; 27(5):607-620. PubMed ID: 28005436
[TBL] [Abstract][Full Text] [Related]
8. What's all the FLAP about?: 5-lipoxygenase-activating protein inhibitors for inflammatory diseases.
Evans JF; Ferguson AD; Mosley RT; Hutchinson JH
Trends Pharmacol Sci; 2008 Feb; 29(2):72-8. PubMed ID: 18187210
[TBL] [Abstract][Full Text] [Related]
9. 5-Lipoxygenase inhibitors: a review of recent patents (2010-2012).
Hofmann B; Steinhilber D
Expert Opin Ther Pat; 2013 Jul; 23(7):895-909. PubMed ID: 23600432
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in the search for novel 5-lipoxygenase inhibitors.
Steinhilber D; Hofmann B
Basic Clin Pharmacol Toxicol; 2014 Jan; 114(1):70-7. PubMed ID: 23953428
[TBL] [Abstract][Full Text] [Related]
11. Discovery of the first dual inhibitor of the 5-lipoxygenase-activating protein and soluble epoxide hydrolase using pharmacophore-based virtual screening.
Temml V; Garscha U; Romp E; Schubert G; Gerstmeier J; Kutil Z; Matuszczak B; Waltenberger B; Stuppner H; Werz O; Schuster D
Sci Rep; 2017 Feb; 7():42751. PubMed ID: 28218273
[TBL] [Abstract][Full Text] [Related]
12. Structure-based, multi-targeted drug discovery approach to eicosanoid inhibition: Dual inhibitors of mPGES-1 and 5-lipoxygenase activating protein (FLAP).
Ho JD; Lee MR; Rauch CT; Aznavour K; Park JS; Luz JG; Antonysamy S; Condon B; Maletic M; Zhang A; Hickey MJ; Hughes NE; Chandrasekhar S; Sloan AV; Gooding K; Harvey A; Yu XP; Kahl SD; Norman BH
Biochim Biophys Acta Gen Subj; 2021 Feb; 1865(2):129800. PubMed ID: 33246032
[TBL] [Abstract][Full Text] [Related]
13. FLAP inhibitors for the treatment of inflammatory diseases.
Sampson AP
Curr Opin Investig Drugs; 2009 Nov; 10(11):1163-72. PubMed ID: 19876784
[TBL] [Abstract][Full Text] [Related]
14. A Single Amino Acid Difference between Mouse and Human 5-Lipoxygenase Activating Protein (FLAP) Explains the Speciation and Differential Pharmacology of Novel FLAP Inhibitors.
Blevitt JM; Hack MD; Herman K; Chang L; Keith JM; Mirzadegan T; Rao NL; Lebsack AD; Milla ME
J Biol Chem; 2016 Jun; 291(24):12724-12731. PubMed ID: 27129215
[TBL] [Abstract][Full Text] [Related]
15. Discovery and optimization of oxadiazole-based FLAP inhibitors.
Bartolozzi A; Abeywardane A; Bosanac T; Broadwater JA; Chen Z; Hutzler JM; Huber JD; Nemoto P; Olague A; Riether D; Simpson T; Takahashi H; Wu L; Zhang Y; Zindell RM
Bioorg Med Chem Lett; 2017 Oct; 27(20):4652-4659. PubMed ID: 28927794
[TBL] [Abstract][Full Text] [Related]
16. Inhibitors of 5-lipoxygenase activating protein: WO 2008/030369.
Tavridou A; Manolopoulos VG
Expert Opin Ther Pat; 2009 Oct; 19(10):1473-6. PubMed ID: 19456278
[TBL] [Abstract][Full Text] [Related]
17. Novel Chemical Series of 5-Lipoxygenase-Activating Protein Inhibitors for Treatment of Coronary Artery Disease.
Lemurell M; Ulander J; Emtenäs H; Winiwarter S; Broddefalk J; Swanson M; Hayes MA; Prieto Garcia L; Westin Eriksson A; Meuller J; Cassel J; Saarinen G; Yuan ZQ; Löfberg C; Karlsson S; Sundqvist M; Whatling C
J Med Chem; 2019 May; 62(9):4325-4349. PubMed ID: 30929436
[TBL] [Abstract][Full Text] [Related]
18. Discovery and Early Clinical Development of an Inhibitor of 5-Lipoxygenase Activating Protein (AZD5718) for Treatment of Coronary Artery Disease.
Pettersen D; Broddefalk J; Emtenäs H; Hayes MA; Lemurell M; Swanson M; Ulander J; Whatling C; Amilon C; Ericsson H; Westin Eriksson A; Granberg K; Plowright AT; Shamovsky I; Dellsèn A; Sundqvist M; Någård M; Lindstedt EL
J Med Chem; 2019 May; 62(9):4312-4324. PubMed ID: 30869888
[TBL] [Abstract][Full Text] [Related]
19. Discovery of AZD6642, an inhibitor of 5-lipoxygenase activating protein (FLAP) for the treatment of inflammatory diseases.
Lemurell M; Ulander J; Winiwarter S; Dahlén A; Davidsson Ö; Emtenäs H; Broddefalk J; Swanson M; Hovdal D; Plowright AT; Pettersen A; Rydén-Landergren M; Barlind J; Llinas A; Herslöf M; Drmota T; Sigfridsson K; Moses S; Whatling C
J Med Chem; 2015 Jan; 58(2):897-911. PubMed ID: 25478788
[TBL] [Abstract][Full Text] [Related]
20. Leukotriene inflammatory mediators meet their match.
Funk CD
Sci Transl Med; 2011 Jan; 3(66):66ps3. PubMed ID: 21248314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
